Literature DB >> 11306570

Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction.

L C van Kempen1, J M Nelissen, W G Degen, R Torensma, U H Weidle, H P Bloemers, C G Figdor, G W Swart.   

Abstract

Activated leukocyte cell adhesion molecule (ALCAM/CD166), a member of the immunoglobulin superfamily with five extracellular immunoglobulin-like domains, facilitates heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. While expressed in a wide variety of tissues and cells, ALCAM is restricted to subsets of cells usually involved in dynamic growth and/or migration processes. A structure-function analysis, using two monoclonal anti-ALCAM antibodies and a series of amino-terminally deleted ALCAM constructs, revealed that homophilic cell adhesion depended on ligand binding mediated by the membrane-distal amino-terminal immunoglobulin domain and on avidity controlled by ALCAM clustering at the cell surface involving membrane-proximal immunoglobulin domains. Co-expression of a transmembrane ALCAM deletion mutant, which lacks the ligand binding domain, and endogenous wild-type ALCAM inhibited homophilic cell-cell interactions by interference with ALCAM avidity, while homophilic, soluble ligand binding remained unaltered. The extracellular structures of ALCAM thus provide two structurally and functionally distinguishable modules, one involved in ligand binding and the other in avidity. Functionality of both modules is required for stable homophilic ALCAM-ALCAM cell-cell adhesion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306570     DOI: 10.1074/jbc.M011272200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Adhesion molecules in endometrial epithelium: tissue integrity and embryo implantation.

Authors:  Harmeet Singh; John D Aplin
Journal:  J Anat       Date:  2009-04-22       Impact factor: 2.610

2.  Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Authors:  Linlin Xu; Khalid S Mohammad; Hao Wu; Colin Crean; Bradley Poteat; Yinghua Cheng; Angelo A Cardoso; Christophe Machal; Helmut Hanenberg; Rafat Abonour; Melissa A Kacena; John Chirgwin; Attaya Suvannasankha; Edward F Srour
Journal:  Cancer Res       Date:  2016-09-07       Impact factor: 12.701

3.  CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis.

Authors:  Syed M A Abidi; Mohammad K Saifullah; Marie D Zafiropulos; Cara Kaput; Michael A Bowen; Calvin Cotton; Nora G Singer
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  The effect of extended passaging on the phenotype and osteogenic potential of human umbilical cord mesenchymal stem cells.

Authors:  Zhe Shi; Liang Zhao; Gengtao Qiu; Ruixuan He; Michael S Detamore
Journal:  Mol Cell Biochem       Date:  2015-01-03       Impact factor: 3.396

5.  Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis.

Authors:  Marc-André Lécuyer; Olivia Saint-Laurent; Lyne Bourbonnière; Sandra Larouche; Catherine Larochelle; Laure Michel; Marc Charabati; Michael Abadier; Stephanie Zandee; Neda Haghayegh Jahromi; Elizabeth Gowing; Camille Pittet; Ruth Lyck; Britta Engelhardt; Alexandre Prat
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

6.  ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier.

Authors:  Ruth Lyck; Marc-André Lécuyer; Michael Abadier; Christof B Wyss; Christoph Matti; Maria Rosito; Gaby Enzmann; Thomas Zeis; Laure Michel; Ana B García Martín; Federica Sallusto; Fabien Gosselet; Urban Deutsch; Joshua A Weiner; Nicole Schaeren-Wiemers; Alexandre Prat; Britta Engelhardt
Journal:  J Cereb Blood Flow Metab       Date:  2016-11-14       Impact factor: 6.200

7.  ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9.

Authors:  Alvaro Gilsanz; Lorena Sánchez-Martín; María Dolores Gutiérrez-López; Susana Ovalle; Yesenia Machado-Pineda; Raquel Reyes; Guido W Swart; Carl G Figdor; Esther M Lafuente; Carlos Cabañas
Journal:  Cell Mol Life Sci       Date:  2012-09-30       Impact factor: 9.261

Review 8.  Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166.

Authors:  Ariana von Lersner; Lenny Droesen; Andries Zijlstra
Journal:  Clin Exp Metastasis       Date:  2019-02-18       Impact factor: 5.150

9.  ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Authors:  Amanda G Hansen; Shanna A Arnold; Ming Jiang; Trenis D Palmer; Tatiana Ketova; Alyssa Merkel; Michael Pickup; Susan Samaras; Yu Shyr; Harold L Moses; Simon W Hayward; Julie A Sterling; Andries Zijlstra
Journal:  Cancer Res       Date:  2014-01-02       Impact factor: 12.701

10.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Authors:  Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Journal:  Cancer Immunol Immunother       Date:  2010-07-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.